In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy. © 2010 by the authors; licensee MDPI, Basel, Switzerland.
CITATION STYLE
Orouji, A., Goerdt, S., & Utikal, J. (2010, June). Systemic therapy of non-resectable metastatic melanoma. Cancers. https://doi.org/10.3390/cancers2020955
Mendeley helps you to discover research relevant for your work.